Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model

The current first‐line treatment for advanced metastatic prostate cancer, i.e. docetaxel‐based therapy, is only marginally effective. The aim of the present study was to determine whether such therapy can be improved by combining docetaxel with Aneustat (OMN54), a multivalent botanical drug candidat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Oncol
Auteurs principaux: Qu, Sifeng, Wang, Kendric, Xue, Hui, Wang, Yuwei, Wu, Rebecca, Liu, Chengfei, Gao, Allen C., Gout, Peter W., Collins, Colin C., Wang, Yuzhuo
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2013
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528545/
https://ncbi.nlm.nih.gov/pubmed/24388358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.12.004
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires